CCEL Stock Risk & Deep Value Analysis
Cryo-Cell International Inc
DVR Score
out of 10
What You Need to Know About CCEL Stock
We analyzed Cryo-Cell International Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran CCEL through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
CCEL Risk Analysis & Red Flags
What Could Go Wrong
The company faces immediate delisting from the NYSE American due to its stockholders' deficit and persistent net losses. Failure to get its compliance plan approved or to secure critical financing would lead to delisting and likely insolvency, decimating shareholder value. The current situation places the company's very existence at risk.
Risk Matrix
Overall
Aggressive
Financial
High
Market
High
Competitive
High
Execution
High
Regulatory
High
Red Flags
- ⚠
NYSE American noncompliance notice (Section 1003(a)) as of March 2026
- ⚠
Stockholders' deficit reported as of November 30, 2025
- ⚠
Net losses in FY2023, FY2024, and FY2025
- ⚠
Current ratio of 0.59 as of November 30, 2025, indicating severe liquidity pressures
Upcoming Risk Events
- 📅
NYSE American delisting due to noncompliance
- 📅
Failure to secure sufficient capital, leading to further financial deterioration or insolvency
When to Reconsider
- 🚪
Formal NYSE American announcement of delisting
- 🚪
Inability to raise significant capital or continued cash burn for two consecutive quarters
- 🚪
Further deterioration of the current ratio below 0.50 or persistent net losses without a clear turnaround plan
Unlock CCEL Risk Analysis & Red Flags
Create a free account to see the full analysis
Investment Thesis
Highly speculative turnaround play betting on a successful resolution of NYSE noncompliance, securing significant emergency financing, and a rapid acceleration of its cell therapy pipeline to capitalize on the large total addressable market. This thesis is currently overshadowed by immediate existential risks and requires aggressive risk tolerance with a very long time horizon for any potential return.
Is CCEL Stock Undervalued?
Unlock the full AI analysis for CCEL
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
CCEL Price Targets & Strategy
12-Month Target
$1.00
Bull Case
$5.00
Bear Case
$0.10
Valuation Basis
Based on a severe discount to current market price, reflecting high probability of delisting or significant dilution without traditional valuation support, assuming highly speculative survival.
Entry Strategy
No entry recommended at current levels due to extreme risk. For highly speculative plays, consider only after clear resolution of NYSE noncompliance and confirmed significant new financing, potentially near $0.50-$1.00 (speculative support levels).
Exit Strategy
Take profit on any significant short-term bounce (e.g., above $2.00-$3.00) if NYSE compliance is announced. Set a stop-loss immediately if NYSE delisting is confirmed or company fails to secure critical financing.
Portfolio Allocation
0.5% for highly aggressive, speculative portfolios only; otherwise 0%.
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Is CCEL Financially Healthy?
Valuation
P/E Ratio
-64.99
Price/Book
-3.10
Price/Sales
1.15
Profitability
Net Margin
-1.49%
Return on Equity
-1.07%
Revenue Growth
-1.25%
EPS
$-1.06
Balance Sheet
Current Ratio
0.63
Quick Ratio
0.57
Does CCEL Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Eroding
Moat Sources
2 Identified
Highly fragile. While historical brand recognition and operational expertise exist in cord blood banking, the severe financial distress and lack of capital for aggressive cell therapy expansion severely compromises the moat's durability against well-funded, innovative competitors in the rapidly evolving biotech landscape.
Moat Erosion Risks
- •Financial insolvency leading to inability to invest in R&D or marketing
- •Intense competition in the broader cell therapy market from larger, better-capitalized players
- •Erosion of customer trust due to ongoing financial and regulatory issues
CCEL Competitive Moat Analysis
Sign up to see competitive advantages
CCEL Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral to Bearish, given the severity of the NYSE noncompliance news.
Institutional Sentiment
Neutral, with an activist stake (Camac Fund) signaling potential for change or perceived undervaluation, but not necessarily broad positive institutional conviction in current operations.
Insider Activity (Form 4)
No specific Form 4 filings identified for buys/sells (period ~Jan 9-Apr 9, 2026).
Options Flow
Normal options activity; no unusual trends reported.
Earnings Intelligence
Next Earnings
No expected date or consensus EPS/revenue estimates in results.
Surprise Probability
Low (due to lack of estimates and visibility)
Historical Earnings Pattern
No discernible pattern available due to limited historical data and recent significant financial distress.
Key Metrics to Watch
Competitive Position
Top Competitor
[Generic: A larger, diversified biotechnology company with an established cell therapy pipeline and strong financial health]
Market Share Trend
Stable in the niche private cord blood banking market, but highly uncertain and likely negligible in the broader, competitive cell therapy market.
Valuation vs Peers
Cannot compare due to lack of valuation metrics for CCEL (e.g., P/E, EV/EBITDA, P/S) and specific competitive peer data. Its negative equity makes traditional valuation difficult.
Competitive Advantages
- •Historical first-mover advantage as the world's first private cord blood bank (since 1992)
- •Established infrastructure and operational expertise in stem cell processing and storage
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive CCEL Stock Higher?
Near-Term (0-6 months)
- •NYSE American compliance plan decision (post-April 8, 2026 submission deadline)
- •Securing new, significant financing to address liquidity and stockholders' deficit
Medium-Term (6-18 months)
- •Stabilization and growth of core cord blood banking business
- •Announcement of a new, substantial partnership or milestone in cell therapy development
Long-Term (18+ months)
- •Successful commercialization of a proprietary cell therapy product
- •Return to sustained profitability and positive cash flow generation
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for CCEL?
- ✓
Positive resolution of the NYSE American noncompliance issue (approval of compliance plan)
- ✓
Announcement of substantial new capital injection or strategic partnership for cell therapy
- ✓
Clear evidence of declining net losses and progress towards cash flow positivity
Bull Case Analysis
See what could go right with Premium
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How Cryo-Cell International Inc Makes Money
Cryo-Cell International primarily operates as a private cord blood bank, offering long-term storage of umbilical cord blood and tissue stem cells for future therapeutic use by families. This established business provides a recurring revenue stream through storage fees. The company is also attempting a strategic pivot into the broader, higher-growth cell therapy sector through research and development and potential partnerships, aiming to leverage its expertise in stem cell processing and storage for new medical treatments and applications. The success of this pivot is currently hindered by significant financial challenges.
Read Full Business Model BreakdownFAQ
What is the DVR Score for Cryo-Cell International Inc (CCEL)?
As of April 9, 2026, Cryo-Cell International Inc has a DVR Score of 1.2 out of 10, placing it in the "Distressed" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Cryo-Cell International Inc?
Cryo-Cell International Inc's market capitalization is approximately $36.7M..
What is the risk level for CCEL stock?
Our analysis rates Cryo-Cell International Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of CCEL?
Cryo-Cell International Inc currently has a price-to-earnings (P/E) ratio of -65.0. This is below the market average, which could indicate the stock is undervalued or facing headwinds.
Is Cryo-Cell International Inc's revenue growing?
Cryo-Cell International Inc has reported revenue growth of -1.3%. Revenue has been declining, which warrants closer examination.
Is CCEL stock profitable?
Cryo-Cell International Inc has a profit margin of -1.5%. The company is currently unprofitable.
How often is the CCEL DVR analysis updated?
Our AI-powered analysis of Cryo-Cell International Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on April 9, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for CCEL (Cryo-Cell International Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.